A retrospective, observational study of efficacy and safety of nusinersen in older adolescent and adult patients with spinal muscular atrophy
Latest Information Update: 02 Dec 2021
Price :
$35 *
At a glance
- Drugs Nusinersen (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Therapeutic Use
- 02 Dec 2021 New trial record